Incidence and mortality trends of metastatic prostate cancer: Surveillance, Epidemiology, and End Results database analysis

Abstract

Introduction: In the past decade, prostate cancer screening decreased, raising the concern of delays in diagnosis and leading to increase in new cases of metastatic prostate cancer. This study evaluated whether these changes may have impacted trends in metastatic prostate cancer incidence and survival.
 Methods: Metastatic prostate cancer diagnoses from 2008–2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) 18 registries. Age-adjusted incidence rates per 100 000 were calculated by time periods and demographic variables. Two-year all-cause and prostate cancer-specific mortality were calculated for patients diagnosed from 2008–2014, and multivariable Cox proportional hazards models were used to evaluate the impact of demographic and clinical variables.
 Results: Incidence rates of metastatic prostate cancer increased by 18% from 2008–2009 to 2014–2016 (Incidence rate ratio [IRR]=1.18, 95% confidence interval [CI] 1.14–1.21). This trend was observed across multiple subgroups but was greatest in non-Hispanic Whites and patients living in counties 0–10% below poverty level. There was an overall decreased risk of all-cause and prostate cancer-specific mortality, but unmarried men and men living in counties >20% below poverty level showed statistically significant increased risk of prostate cancer-specific mortality.
 Conclusions: Non-Hispanic Whites and the wealthiest subgroups had the largest increase in incidence of metastatic prostate cancer since 2008. Despite trends of decreased risk of prostate cancer-specific mortality, we found certain populations experienced increases in mortality risk. Studies exploring the role of socioeconomic factors on screening and access to newer treatments are needed.

The impact of race on survival in metastatic prostate cancer: a systematic literature review

“…The commonly reported racial groups discussed across these studies were Black (i.e., Black, Non-Hispanic Black), White (i.e., White, Non-Hispanic White, Non-Black), Hispanic 1 , Asian (i.e., Asian, Non-Hispanic Asian, Asian/Pacific Islander), and American Indian/Alaska Native (AI/AN) (i.e., AI/AN, Native American). Twenty-seven [ 20 , 22 , 25 , 27 , 30 , 31 , 33 – 36 , 38 , 41 , 48 , 49 , 51 – 58 , 60 , 62 , 70 , 71 , 78 ] of the 54 studies reported results on overall survival (OS) or all-cause mortality, 11 studies [ 21 – 24 , 26 , 31 , 37 , 38 , 44 , 50 , 61 ] reported results on prostate cancer specific mortality (PCSM), and 11 studies [ 29 , 32 , 39 , 46 , 62 – 65 , 73 , 77 , 80 ] reported results on OS or PCSM in patients on specific mPC treatments, with some of the studies reporting on more than one survival outcome. Nine studies [ 3 , 28 , 40 , 42 , 43 , 45 , 47 , 59 , 79 ] reported only descriptive data, described racial groups other than Black, White, Hispanic, Asian, or Native American, such as Maori, Thai, Malaysian, or conducted separate analyses within each racial group.…”

Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: An updated systematic review and meta-analysis

“…Despite a 5-year relative survival rate of >99% for localized disease, mPCa remains the second leading cause of cancer-related deaths in men, with a 5-year relative survival rate of 30.2%. Prior studies have demonstrated an increase in the diagnosis of de novo mPCa in recent years, perhaps related to the United States [ 38 ]. Therefore, although the birth of ARTA has opened a new horizon for mPCa treatment, it is still an incurable disease and requires continuous research.…”

Influencing factors for mortality in prostate cancer patients with T1 and T2 stage: a retrospective cohort study

“…The data for analysis were obtained from the SEER database, which covered approximately 27.8% of the United States population from 18 regions (including Los Angeles, New Mexico, Greater Georgia, etc.) ( 15 ). In this cohort study, male patients with localized PCa whose age of pathological diagnosis was between 25–80 years old were selected from the SEER database between 2004 and 2016.…”